Skip navigation

Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12128/16134
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWawrzkiewicz-Jałowiecka, Agata-
dc.contributor.authorKowalczyk, Karolina-
dc.contributor.authorTrybek, Paulina-
dc.contributor.authorJarosz, Tomasz-
dc.contributor.authorRadosz, Patrycja-
dc.contributor.authorSetlak, Marcin-
dc.contributor.authorMadej, Paweł-
dc.date.accessioned2020-09-28T07:24:53Z-
dc.date.available2020-09-28T07:24:53Z-
dc.date.issued2020-
dc.identifier.citationInternational Journal of Molecular Sciences, Vol. 21 (2020), Art. No. 7054pl_PL
dc.identifier.issn1661-6596-
dc.identifier.issn1422-0067-
dc.identifier.urihttp://hdl.handle.net/20.500.12128/16134-
dc.description.abstractIn a healthy female reproductive system, a subtle hormonal and metabolic dance leads to repetitive cyclic changes in the ovaries and uterus, which make an effective ovulation and potential implantation of an embryo possible. However, that is not so in the case of polycystic ovary syndrome (PCOS), in which case the central mechanism responsible for entraining hormonal and metabolic rhythms during the menstrual cycle is notably disrupted. In this review we provide a detailed description of the possible scenario of PCOS pathogenesis. We begin from the analysis of how a set of genetic disorders related to PCOS leads to particular malfunctions at a molecular level (e.g., increased enzyme activities of cytochrome P450 (CYP) type 17A1 (17a-hydroxylase), 3b-HSD type II and CYP type 11A1 (side-chain cleavage enzyme) in theca cells, or changes in the expression of aquaporins in granulosa cells) and discuss further cellular- and tissue-level consequences (e.g., anovulation, elevated levels of the advanced glycation end products in ovaries), which in turn lead to the observed subsequent systemic symptoms. Since gene-editing therapy is currently out of reach, herein special emphasis is placed on discussing what kinds of drug targets and which potentially active substances seem promising for an effective medication, acting on the primary causes of PCOS on a molecular level.pl_PL
dc.language.isoenpl_PL
dc.rightsUznanie autorstwa 3.0 Polska*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/pl/*
dc.subjectpolycystic ovary syndrome (PCOS)pl_PL
dc.subjectmolecular mechanismpl_PL
dc.subjectnovel therapiespl_PL
dc.subjectinositolspl_PL
dc.subjectGABApl_PL
dc.subjectkisspeptinpl_PL
dc.subjectberberinepl_PL
dc.subjectnaringeninpl_PL
dc.subjectAQPs-oriented therapypl_PL
dc.titleIn Search of New Therapeutics—Molecular Aspects of the PCOS Pathophysiology: Genetics, Hormones, Metabolism and Beyondpl_PL
dc.typeinfo:eu-repo/semantics/articlepl_PL
dc.identifier.doi10.3390/ijms21197054-
Appears in Collections:Artykuły (WNŚiT)

Files in This Item:
File Description SizeFormat 
Wawrzkiewicz-Jalowiecka_In_search_of_new_therapeutics.pdf936,95 kBAdobe PDFView/Open
Show simple item record


Uznanie Autorstwa 3.0 Polska Creative Commons License Creative Commons